Actinogen Medical progresses in XanaMIA Phase 2b/3 trial for Alzheimer’s disease
Actinogen Medical Limited (ASX: ACW) has announced a major milestone in its ongoing XanaMIA Phase 2b/3 clinical trial, aimed at treating biomarker-positive mild to moderate ... Read More
Actinogen Medical makes bold A$11.1m move to boost Alzheimer’s drug trial
Actinogen Medical has raised 11.1 million AUD in a significant capital raise led by its CEO, Dr. Steven Gourlay, who personally invested 1 million AUD. ... Read More